Friday, 25 September 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 15, 2025

4 Medical Device Stocks to Buy for Healthy Returns in 2026

View original at finance.yahoo.com
4 Medical Device Stocks to Buy for Healthy Returns in 2026 2025 brought ups and downs for the MedTech industry. Under President Trump’s second term, shifting trade policies, including new and heightened threats of tariffs, sanctions and other restrictions, created significant uncertainties…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Intuitive Surgical carries a Zacks Rank #1 (Strong Buy)

    80% confidence

  • For 2026, Insulet revenues and EPS are expected to grow 19.8% and 26.3%, respectively

    80% confidence

  • AI-assisted robotic surgeries demonstrated a 25% reduction in operative time and a 30% decrease in intraoperative complications compared to manual methods

    80% confidence

  • More Omnipod 5 rollouts are planned in 2026, while Libre 3 integration in the United States remains on track for the first half of 2026

    80% confidence

  • IDEXX's 2026 revenues and EPS are likely to increase 8.9% and 11.6%, respectively

    80% confidence

  • Boston Scientific carries a Zacks Rank #2 (Buy)

    80% confidence

  • For 2026, Intuitive Surgical revenues are expected to grow 14.3%, whereas earnings per share are expected to rise 11.2%

    80% confidence

  • For 2026, Boston Scientific revenues and EPS are expected to jump 11.1% and 13.6%, respectively

    80% confidence

  • Insulet holds a Zacks Rank #2 (Buy)

    80% confidence

  • M&A activity shifted toward fewer but larger deals, with average transaction size rising 11% from 2024

    80% confidence

  • The digital twins market is forecasted to expand at a 16.6% CAGR between 2025 and 2032

    80% confidence

  • IDEXX Laboratories carries a Zacks Rank #2 (Buy)

    80% confidence

  • The MedTech industry generated $584 billion in revenues in 2025, marking its seventh consecutive year of top-line growth

    80% confidence

  • The global medical device market is expected to expand at a CAGR of 5.94% from 2026 to 2035

    80% confidence

  • Through September 2025, the FDA's list of AI-enabled device authorizations included more than 250 devices, with Radiology taking the lead

    80% confidence

  • IDEXX plans to expand the Cancer Dx franchise in 2026 by adding mast cell tumor and introducing it in international markets

    80% confidence

Data points we hold from this source

U.S. Food and Drug Administration · ai device authorizations250 devices
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI Agents Scale Up Through Partnerships and Funding, But Data Readiness Lags Ambition
A wave of vertical AI-agent startups (Swarm, Veridox, Avallon AI, DA2, F2, Earthian, Meanwhile, Covecta, Penguin AI, Maisa AI) is being funded and profiled just as major infrastructure players — Microsoft/Mistral, Siemens/NVIDIA, and Manulife/Microsoft — cement enterprise AI governance and compute partnerships. Yet a Google Cloud report shows AI agents still lack access to the majority of company data (only 45% on average), and insider selling at incumbent C3.ai signals investor caution even as adoption intent (100% planned agentic AI use within two years) races ahead of actual data infrastructure.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,984
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,984 facts checked against source5,306 source documents archived
Query this data → isubstrate.com
4 Medical Device Stocks to Buy for Healthy Returns in 2026 — Source | Via News | ViaNews EU